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Abstract
Background: Platinum compounds are the mainstay of chemotherapy for lung cancer. Unfortunately treatment
failure remains a critical issue since about 60 % of all non-small cell lung cancer (NSCLC) patients display intrinsic
platinum resistance.
Methods: We analyzed global gene expression profiles of NSCLC clones surviving a pulse treatment with cisplatin
and mapped deregulated signaling networks in silico by Ingenuity Pathway Analysis (IPA). Further validation was
done using siRNA.
Results: The pooled cisplatin-surviving NSCLC clones from each of the biological replicates demonstrated
heterogeneous gene expression patterns both in terms of the number and the identity of the altered genes.
Genes involved in Wnt signaling pathway (Dickkopf-1, DKK1), DNA repair machinery (XRCC2) and cell-cell/cell-matrix
interaction (FMN1, LGALS9) were among the top deregulated genes by microarray in these replicates and were
validated by q-RT-PCR. We focused on DKK1 which previously was reported to be overexpressed in NSCLC patients. IPA
network analysis revealed coordinate up-regulation of several DKK1 transcriptional regulators (TCF4, EZH2, DNAJB6 and
HDAC2) in cisplatin-surviving clones from that biological replicate. Knockdown of DKK1 by siRNA sensitized for cisplatin
in two different NSCLC cell lines and in ovarian A2780 cells, but not in the A2780 cis subline made resistant to cisplatin
by chronic exposure, suggesting a role of DKK1 in intrinsic but not acquired platinum refractoriness.
Conclusions: We identified DKK1 as a possible marker of a cisplatin-refractory phenotype and as a potential novel
therapeutic target to improve platinum response of NSCLC cells.
Background
Lung cancer (LC) is the tumor type with the highest
number of cancer-associated deaths worldwide [1]. LC
is histologically categorized into non-small cell lung
cancer (NSCLC) and small cell lung cancer (SCLC) of
which NSCLC constitutes about 85 % of all cases and
is further divided into adeno-, squamous cell- and
large cell carcinoma [1]. Surgery, if possible, is the
treatment of choice for stage I, II and IIIa NSCLC
with chemotherapy primarily being used as adjuvant
or neoadjuvant treatment [2]. For non-resectable or
advanced NSCLC, which constitutes the majority of
cases, multimodal chemotherapy alone or in combin-
ation with radiotherapy is the main treatment option
[2]. The chemotherapy regimen usually consists of a
cisplatin or a carboplatin doublet combined with gemcita-
bine, vinorelbine, paclitaxel, pemetrexed or docetaxel [2].
The primary mechanism of cisplatin action at clinically
relevant doses is to induce DNA damage. This is achieved
through covalent crosslinking of platinum to the cellular
DNA, leading to the formation of crosslinks in the same
DNA strand (intra-strand crosslink) or between the two
different strands, so called inter-strand crosslinks, ICLs
[3]. Subsequently, the ICLs physically impede the progress
of the replication fork and transcriptional machinery caus-
ing replication stress and blocked transcription process,
leading to activation of the intra-S checkpoint, and if the
lesions are too extensive, induction of cell death [3].
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Cisplatin resistance is still a major obstacle for the
clinical management of NSCLC. At the molecular level,
a cisplatin-refractory phenotype can be a result of: (I)
failure to reach the DNA (pre-target resistance), (II) im-
peded induction of DNA lesions (on-target resistance),
(III) malfunctioning of cell death pathways (post-target
resistance), and (IV) activation of pro-survival signaling
pathways that are not directly influenced by cisplatin,
but abolish its death-inducing capacity (off-target resist-
ance), reviewed in [4].
Although the molecular mechanisms underlying cis-
platin refractoriness have been investigated for over
a decade, only two biomarkers that can predict cis-
platin sensitivity and distinguish responders from
non-responders have reached the clinic, excision re-
pair cross-complementing rodent repair deficiency,
complementation group 1 (ERCC1) and ribonucleotide re-
ductase M1 (RRM1), respectively. NSCLC cases whose
specimen lacked ERCC1 expression had a more promin-
ent response to adjuvant cisplatin treatment and hence
ERCC1 expression holds promise as a predictive bio-
marker. [5]. Low RRM1 mRNA expression was linked to a
better response to a cisplatin/gemcitabine regimen [6].
However, neither ERCC1 nor RRM1 were correlated to
cisplatin sensitivity when basal mRNA expression was
analyzed in 12 NSCLC cell lines [7] reflecting the
complexity in finding biomarkers which can predict
cisplatin responsiveness.
Other studies have aimed to characterize signaling cas-
cades which could drive cisplatin-survival and hence con-
stitute putative resistance-driving networks in lung cancer
by focusing on short term effects of continuous cisplatin
treatment i.e. from hours up to a few days, or by creating
resistant sub-lines after repeated cisplatin pressure which
also could generate new driving mutations [4, 8]. In this
study, we explored the intrinsic properties of the cisplatin-
surviving sub-population of NSCLC cells 9 days after a
single one hour-treatment. This treatment regimen was
chosen to reflect the short pulse of drug used clinically,
where administration time is typically 30 minutes to two
hours (http://www.cisplatin.org/treat.htm).
Using this approach, we found a heterogeneous gene
expression pattern when analyzing three biological repli-
cates of cisplatin-surviving NSCLC clones. Among the
different biological replicates we identified genes in
diverse cellular pathways in these cisplatin-survivors e.g.
dickkopf-1 (DKK1), X-ray repair cross-complementing
protein 2 (XRCC2), formin 1 (FMN1) and lectin,
galactoside-binding, soluble 9 (LGALS9). Through bio-
informatics analysis, we identified TCF4, EZH2, DNAJB6
and HDAC2 as co-regulated, upstream regulators of
DKK1, which may form a signaling circuit that enhances
the effect of DKK1 in enabling survival after cisplatin
treatment. By siRNA-mediated knockdown of DKK1
in NSCLC and ovarian cancer cells, the colony forming
capacity and/or cell survival upon cisplatin treatment was
reduced significantly. In contrast, plasmid-based overex-
pression of FMN1 did not clearly increase cisplatin sensi-
tivity of NSCLC cells. Thus our data suggest that DKK1
should be further explored as a potential biomarker of
cisplatin refractoriness and/or as a target for cisplatin-
sensitizing strategies in NSCLC and other tumor types.
Methods
Cell lines and culture conditions
In the present study human NSCLC cell lines U-1810 and
U-1752 (gifts from Uppsala University, Sweden [9]), A549,
H23, H125, H157, H661 and H1299 (ATCC, Manas-
sas, VA, USA) were used. Cells were cultured at 37 °C and
5 % CO2 in RPMI-1640 medium containing 2 mM L-glu-
tamine, supplemented with 10 % heat-inactivated fetal bo-
vine serum (both from Invitrogen, Stockholm, Sweden). In
addition, the human ovarian cancer cell lines A2780 and
its cisplatin-resistant subline A2780 cis (Sigma-Aldrich,
Stockholm, Sweden) were used and cultured as above. To
maintain the cisplatin resistance of A2780 cis cells, 1 μM
cisplatin was added to the culture medium every 3rd-4th
passage. All cell lines used in the study were established
and already published on (see above). No ethical permits
were therefore required for their use in the current study.
Colony formation assay of cisplatin-refractory NSCLC
clones
NSCLC cells were seeded in duplicate in Cell + culture
dishes (Sarstedt, Landskrona, Sweden) at a density of
500 cells/100 mm dish and were after 24 h treated with
cisplatin (2.5-20 μM, Hospira Nordic AB, Stockholm,
Sweden) for one hour. Cells were rinsed in PBS after
treatment and allowed to form colonies over a 9-days
period. The resulting colonies were visualized by staining
with crystal violet (0.5 % crystal violet in 25 % methanol)
or collected for RNA extraction (see below). For clono-
genic survival analyses, colonies consisting of at least 50
cells were counted under a light microscope using dupli-
cate plates from three independent experiments. For
retreatment experiments, cell colonies were instead tryp-
sinized and pooled, counted and seeded in 96-well plates
for MTT or in new Cell + plates for treatment the next
day using the same setup as in the first treatment.
RNA extraction and gene expression analysis
In order to have enough RNA for the gene expression
analysis all the surviving clones from each biological repli-
cate were pooled and subjected to total RNA extraction
using Trizol (Invitrogen) as described [10]. Cleanup was
performed using the RNeasy Mini kit (Qiagen, Sollentuna,
Sweden) and RNA quality was analyzed using an
Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA,
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USA). Analysis of gene expression was performed
using Affymetrix® whole transcript GeneChip® Hu-
man Gene 1.0 ST arrays (Affymetrix, Santa Clara,
CA, USA), which contains probes for 28 869 genes.
cDNA was prepared from 500 ng total RNA, labeled and
hybridized to arrays using standard protocols (http://
www.affymetrix.com/support/technical/product_updates/
wt_1_1_assay.affx). Primary array processing was per-
formed using the Affymetrix GeneChip® Command Con-
sole® Software (AGCC, version 1.1) and subsequent
analysis was conducted using the Affymetrix Expression
Console (EC, version 1.1).
Post-acquisition data processing was carried out using
previously described methods (http://www.affymetrix.com/
estore/browse/level-1-instruments-software-landingpa-
ge.jsp?expand=true&parent=35854&category=35919).
Briefly, probe logarithmic intensity error estimation (PLIER)
was used to enhance probe signals by summarization; per-
fect match GC composition-based background correction
(PM GCBG) was applied for background correction and
global median to normalize the signals. For further ana-
lysis, genes with signal intensity below 10 after back-
ground correction were excluded to avoid taking genes
whose alterations are not easily distinguished from noise
into subsequent analyses. In addition, genes correspond-
ing to uncharacterized proteins, hypothetical proteins pre-
fixed with the letters LOC, and small nucleolar RNAs
(SNORD) were also excluded from the analysis since in
this study we aimed to focus on well annotated, protein-
coding mRNAs. The raw data presented and used in
this article is deposited in NCBI's Gene Expression
Omnibus (GEO) [11] as described in the Availability
of supporting data section. Hierarchical clustering
analysis was performed using Partek Genomics Suite
version 6.6 (Partek Inc., St. Louis, MO, USA) in
which clustering was based on rows and columns
using Euclidean distance for row/column dissimilarity
and average linkage as row/column method.
Quantitative real-time PCR (q-RT-PCR)
For the q-RT-PCR validation of gene expression data,
500 ng of the same RNA batch was used as template for
cDNA synthesis using Reverse Transcription Reagents
with random hexamer primers (Applied Biosystems,
Stockholm, Sweden) as previously described [12]. To
quantify mRNA expression levels, cDNA, Fast SYBR®-
Green Master Mix (Applied Biosystems) and the follow-
ing primers (DKK1, forward: CGG GAA TTA CTG
CAA AAA TGG AAT ATG TG, reverse: AAG CTT
TCA GTG ATG GTT TCC TCA ATT; XRCC2, forward:
GGC GAT GTG TAG TGC CTT CCA TA, reverse:
TTT CTT TCA AGG AAC TTC TAC CTT CAA GTC;
LGALS9, forward: AGC TCC AGT GGA ACC AGG
TTT G, reverse: TCA TTT CCA CTG AAG CCA GTC
TGA A; ERCC1, forward: CTG CTT GTC CAG GTG
GAT GTG AAA, reverse: GAT ACA CAT CTT AGC
CAG CTC CTT GAG. RRM1, forward: CCT ATG AGG
GCT CTC CAG TTA GCA A, reverse: CCA GTC CCA
TAG GTC TGT AGG AGT AAC; 18S, forward: GCT
TAA TTT GAC TCA ACA CGG GA, reverse: AGC
TAT CAA TCT GTC AAT CCT GTC C) (from DNA
technology, Risskov, Denmark) or FMN1 (cat.#
QT01330315, Qiagen) were mixed in a final volume of
10 μl. The Fast PCR program was used on the ABI Prism
7900HT Sequence detection system (Applied Biosystems),
which is initiated at 95 °C for 20 s, followed by 45 amplifi-
cation cycles (95 °C, 1 s; 60 °C, 20 s). For each biological
sample two technical replicates were used and the relative
RNA expression obtained by applying the 2−ΔΔCt method
[13] in which 18S rRNA was used as an internal control.
Immunoblotting
Proteins were extracted using RIPA buffer containing
50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA,
0.1 % Na-deoxycholate and 1 % NP-40. Thirty micro-
gram of total protein was loaded onto ready-to-use 4-12 %
Bis-Tris gels (NuPAGE, Invitrogen), separated by electro-
phoresis and thereafter blotted onto nitrocellulose mem-
brane (Trans-Blot, Bio-Rad, Hercules, CA, USA). After
blocking in Odyssey blocking buffer, diluted 1:1 with
TBST (LI-COR Biosciences, Lincoln, NE, USA), primary
antibodies recognizing phosphoserine 9 GSK3B, phospho-
serine 473 AKT, total AKT and PI3-kinase (5558, 9271,
4685 and 4257, respectively, Cell Signaling Technology,
Danvers, MA, USA), p21WAF1/Cip1 or Bcl-2 (sc-756
and sc-509, Santa Cruz Biotechnology, Dallas, TX,
USA) was added. To control for loading differences,
GAPDH (ab9484, Abcam, Cambridge, UK) or β-tubulin
(Sigma-Aldrich) was used. To visualize primary antibody
binding on the membranes, secondary goat-anti-mouse or
goat-anti-rabbit antibodies directly conjugated to infrared
dyes, IRDye (LI-COR Biosciences) were applied and
resulting protein expression levels analyzed by the
Odyssey®Sa Infrared Imaging System (LI-COR Biosciences).
Ingenuity Pathway Analysis
Ingenuity Pathway Analysis tool (IPA; Ingenuity Systems,
Redwood city, CA) was used to create in silico interaction
networks of DKK1 based on published, publically available
data, showing direct upstream transcription regulators of
DKK1 as well as proteins downstream of DKK1.
MTT cell viability assay
To assess cytotoxic response of cisplatin, MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium) cell via-
bility assay was used in a 96-well format as previously
described [14]. Three technical replicates were made for
each biological sample and assayed after a continuous
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exposure to cisplatin for 72 h. For NSCLC cells, 5 000
cells/well were used and in A2780 and A2780 cis experi-
ments, 15 000 cells were seeded per well. Cell viability
was assessed by adding the MTT reagent as indicated
[14] and is given as % of untreated cells whose viability
was set to 100 %. For the NSCLC cells, cisplatin sensitiv-
ity was calculated using the area under curve (AUC)
from the survival curve.
DKK1 siRNA transfection
To inhibit DKK1 expression in U-1810, A549 and A2780/
A2780 cis cells, 50 nM siRNA against DKK1 (si1 = s22721:
Sense: GCU UCA CAC UUG UCA GAG Att, Antisense:
UCU CUG ACA AGU GUG AAG Cct; si2 = s22722:
Sense: GGC UCU CAU GGA CUA GAA Att, Antisense:
UUU CUA GUC CAU GAG AGC Ctt, Invitrogen) or
non-targeting siRNA (NT, 4390843, Invitrogen) was added
to the cells during 72 h (U-1810, A549) or 96 h (A2780,
A2780 cis) using Dharmafect 1 (0.1 %) from Dharmacon
(Thermo Scientific, Lafayette, CO, USA). Cells were
subsequently detached and frozen for RNA extraction
or were re-plated for cell death and signaling profiling
analysis (collected 24-72 h after cisplatin exposure),
for MTT or for colony formation capacity after cis-
platin treatment.
Overexpression of FMN1 and assessment of cisplatin
sensitivity
FMN1 was overexpressed in U-1810 cells by transfecting
cells with the FMN1 open reading frame cDNA inte-
grated in the pCMV6-AC-GFP plasmid (OriGene,
Rockville, Maryland, USA), using Lipofectamine LTX
reagent (Invitrogen, Germany). Briefly, U1810 cells were
seeded in 6-well plates and transfected with 2 μg of
pCMV6-AC-GFP FMN1 plasmid for 24 h. As a control,
cells only treated with Lipofectamine were used. The next
day, media was removed, and normal growth media
(RPMI-1640) was added to each well for another 24 h.
Western blot analysis was used to confirm the overexpres-
sion of FMN1 at the point of cisplatin treatment using a
FMN1 antibody (Abcam, Cambridge, UK). To assess the
effect on proliferation and cisplatin sensitivity, cells were
seeded in 96-well plates (8000 cells/well), and the next day
treated with indicated concentrations of cisplatin for
72 h. The cytotoxicity of cisplatin was determined
with (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazo-
lium) (MTT) assay as described above. Survival of
cells is given by comparing the absorbance in treated
cells relative to the absorbance in cells only treated
with Lipofectamine. Three separate transfections were
performed with triplicate technical repeats in the
MTT. Data presented is the mean ± SEM.
Statistical analysis
Data given is the mean ± S.D. from three separate exper-
iments, unless otherwise indicated. A two-tailed un-
paired Student’s t-test was used. P<0.05 was considered
for statistical significance.
Results
Cisplatin-refractory NSCLC surviving clones show a
heterogeneous gene expression pattern
In order to identify underlying signaling aberrations
of the NSCLC cells which could govern a cisplatin-
refractory phenotype, the gene expression pattern of
long-term cisplatin-surviving NSCLC clones was ana-
lyzed in three biological replicates and compared with
that of untreated cells which formed colonies, as out-
lined in Fig. 1a. First, cytotoxic profiling of NSCLC
U-1810 cells after cisplatin treatment was carried out
using concentrations in the range achievable in
plasma from patients (5 μM) [15] (Fig. 1b). The U-
1810 cells displayed a clear cisplatin-refractory pheno-
type as 2.5, 5 and 10 μM cisplatin only reduced the
colony forming capacity by 10 %, while at 20 μM cisplatin,
the reduction was 20 % (p = 0.02) (Fig. 1b). Although the
difference in clonogenicity was minor, 10 μM cisplatin
caused a 2-fold decrease in total cell number (Fig. 1c).
This demonstrates that at therapeutically relevant concen-
trations, the reduction in growth rate is more pronounced
than the effects on colony number after platinum
treatment.
Next we pooled the surviving NSCLC clones from un-
treated or cisplatin-treated cells within each biological
replicate and performed gene expression array analysis.
First, we sought to identify genes which were consist-
ently altered in all three biological replicates examined
using a cutoff value of 1.5-fold up- or down-regulated.
From this analysis only one gene, formin 1 (FMN1), pre-
viously reported to control cell morphology by regulat-
ing focal adhesion and motility [16], was regulated in all
replicates. Despite similar treatment conditions in the
three biological replicates of cells, yet they showed some
differences in cisplatin response (Fig. 1b).
We reasoned that as cisplatin may confer resistance in
multiple ways, the heterogeneity among the biological
replicates could possibly reflect a biologically heteroge-
neous response but it cannot be ruled out that also ex-
perimental variations by other means could contribute
to the observed results. As a next step we therefore ana-
lyzed alterations in gene expression in each biological
replicate separately. In total, 2720 genes were up- and
2725 genes were down-regulated in the cisplatin-
surviving clones from the first replicate, while 1238 and
50 genes were up- and 46 and 84 genes were down-
regulated in the surviving clones from the second and
third replicates, respectively (Table 1). Importantly, the
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difference in direction of regulation, magnitude as well
as in the number of altered genes among the three bio-
logical replicates varied (Additional file 1, Table 1). This
suggests that there is indeed considerable heterogeneity
among the surviving NSCLC clones on the transcrip-
tome level, which also was evident by hierarchical clus-
tering (Additional file 1).
By analyzing each biological replicate separately a
number of genes with altered expression in cisplatin-
surviving NSCLC clones as compared to untreated
counterparts were evident. Among the top 10 regulated
genes from the cisplatin-refractory NSCLC clones were
dickkopf-1 (DKK1) and X-ray repair cross-complementing
protein 2 (XRCC2) from the first replicate, and lectin,
galactoside-binding, soluble 9 (LGALS9) from the third
replicate (Fig. 2, labeled with *). These proteins have been
implicated in the prognosis of different tumors [17–19].
DKK1 is a secreted protein that inhibits bone formation
through inhibition of Wnt signaling pathway and has
been shown to be highly expressed in NSCLC tumor
material and serum from NSCLC patients as com-
pared to patients with no tumor [18, 20]. DKK1 has
also been shown to promote invasion and migration
in NSCLC cells in vitro [21]. In our gene expression
analysis, DKK1 was 24-fold higher expressed in the
cisplatin-refractory clones than in the untreated clones in
that biological replicate (Fig. 2, top panel).
In accordance with other studies which demonstrated
a role of homologous recombination (HR) in inter-
strand crosslink tolerance [19], we observed an 8-fold
up-regulation of XRCC2 in cisplatin-refractory NSCLC
clones. Finally, in the third biological replicate
LGALS9 expression was 1.7-fold higher in residual
NSCLC clones than in untreated clones (Fig. 2, lower
panel). LGALS9 is a member of beta-galactoside-binding
proteins (galectins) and has been described to be a nega-
tive regulator of the antitumor immune T cells [17]. Im-
portantly, although we found that each of these genes
were up-regulated in different biological replicates of
cisplatin-refractory NSCLC residual clones, their expres-
sion levels were largely unchanged in the other replicates
further illustrating that the NSCLC residual clones that
survive cisplatin pulse treatment have heterogeneous gene
expression patterns.
Validation of altered FMN1, DKK1, XRCC2 and LGALS9
mRNA expression in cisplatin-refractory NSCLC residuals
Next, we set out to validate the observed alterations in
FMN1, DKK1, XRCC2 and LGALS9 expression by q-RT-
PCR using the same RNA as was applied in the
Table 1 Number of regulated genes in cisplatin-surviving clones
No. of genes (≥1.5-fold)
Up-regulated genes Down-regulated genes
Replicate 1 2720 2725
Replicate 2 1238 46
Replicate 3 50 84
Replicate 1 + 2 19 8
Replicate 1 + 3 9 11
Replicate 2 + 3 7 0
Replicate 1 + 2 + 3 0 1
The numbers of differentially expressed genes in each replicate of the NSCLC
residual U-1810 clones after cisplatin treatment.
Fig. 1 Colony formation assay after treatment of U-1810 cells with cisplatin. a Schematic outline of the experiments. NSCLC U-1810 cells were either
untreated or cisplatin-treated for 1 h. Cells were then allowed to form colonies over 9 days in drug-free media. One set of dishes was stained with
0.5 % crystal violet and the number of colonies was counted. Other sets of dishes were used for extraction of total RNA for gene expression profiling.
Ingenuity Pathway Analysis software was used to identify altered cellular networks based on differential gene expression (>1.5 fold up- or
down-regulated) relative to untreated cells. A number of genes were selected for further validation by q-RT-PCR. b Relative clonogenic survival of
NSCLC U-1810 cells after treatment with 2.5-20 μM cisplatin. For each concentration, three biological replicates were performed where the survival of
untreated cells was set to one. c Total cell number was calculated using a haemocytometer for the surviving clones after 10 μM cisplatin. ***; p<0.005
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microarray analysis (Fig. 3). In the global transcrip-
tome analysis, FMN1 expression was reduced in the
cisplatin-surviving NSCLC residual clones by about
50 % (Fig. 3a, left panel). Accordingly, q-RT-PCR re-
vealed a similar down regulation of FMN1 mRNA
expression in all three replicates confirming the observed
alteration of this gene in cisplatin-refractory clones (Fig. 3a,
right panel). We also tested if overexpression of FMN1 in
NSCLC U-1810 cells could sensitize for cisplatin treat-
ment (Additional file 2). Albeit a clear overexpression of
FMN1 was achieved (Additional file 2A) and FMN1 alone
caused a slight decrease in cell viability, no statistically
significant effect on cisplatin response was evident
(Additional file 2B). Hence this data suggest that the ob-
served down regulation of FMN1 in cisplatin refractory
clones is not directly associated with resistance, or acts in
concert with other signaling components in order to regu-
late cisplatin responsiveness.
DKK1, the top scored gene in the first biological
replicate showed a 25-fold increase in the cisplatin-re-
fractory clones by global gene expression profiling and a
15-fold up-regulation by q-RT-PCR analysis (Fig. 3b). In
addition, XRCC2 expression was increased about 10-fold
when analyzed by either microarray or q-RT-PCR, in rep-
licate 1 (Fig. 3b). Finally, LGALS9 expression was 1.7-fold
higher in NSCLC cisplatin-refractory clones as analyzed
by microarray and similarly 1.4-fold higher than untreated
cells by q-RT-PCR in replicate 3 (Fig. 3b). In conclusion,
we were able to validate the altered expression of FMN1,
DKK1, XRCC2 and LGALS9 observed with gene expres-
sion profiling.
DKK1 pathway proteins show concurrent up-regulation in
cisplatin-refractory NSCLC clones
To further explore the DKK1 pathway in the cisplatin-
refractory phenotype of NSCLC cells and to delineate
putative mechanisms, Ingenuity Pathway Analysis (IPA)
was used to map upstream regulating and downstream
proteins of DKK1 (Fig. 4). First, an interaction network
based on published literature composed of proteins
regulating DKK1 was created and from this the tran-
scriptional regulators of DKK1 were selected for further
analysis (Fig. 4a). In total, IPA identified 16 transcrip-
tional regulators of DKK1 out of which 4 showed a con-
current up-regulation in the NSCLC cisplatin-surviving
clones (Fig. 4a). Thus the expression of transcription fac-
tor 4 (TCF4), enhancer of zeste homolog 2 (EZH2), DnaJ
homolog subfamily B member 6 (DNAJB6) and his-
tone deacetylase 2 (HDAC2) showed 2.0-, 3.0-, 1.6-
and 2.3-fold increase, respectively, in the cisplatin re-
fractory NSCLC clones relative to the corresponding
untreated clones of replicate 1. The finding that dif-
ferent factors in the DKK1 pathway are coordinately
up-regulated in cisplatin-surviving NSCLC clones may
point towards a role for DKK1 in driving a cisplatin-
refractory phenotype.
In order to identify signaling components downstream
of DKK1 which could have a role in the control of a
cisplatin-refractory phenotype, a similar network was
constructed by IPA. Albeit some direct protein-protein
interactions are reported, only indirect targets of DKK1
were available in IPA. Cyclin-dependent kinase inhibitor
1A (CDKN1A, also called p21WAF1/Cip1) [22, 23],
microtubule-associated protein tau (MAPT) [24–26],
Fig. 2 Cisplatin-surviving NSCLC clones have heterogeneous gene
expression patterns. Global transcriptome analysis was performed on
RNA extracted from cisplatin-surviving (1 h, 10 μM) versus untreated
NSCLC clones. Fold changes in the expression (relative to untreated
sample) of the top 10 up- and down-regulated genes from each
biological replicate are depicted separately; replicate 1 (upper panel),
replicate 2 (middle panel), replicate 3 (lower panel). Stars mark candidate
genes that were subsequently validated by q-RT-PCR
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mitogen-activated protein kinase 1 (MAPK1, ERK2)
[27], disks large homolog 4 (DLG4) [28], glycogen syn-
thase kinase 3 beta (GSK3B) [28, 29] and ephrin type-
B receptor 2 (EPHB2) [30] were found to be indirectly
regulated by DKK1 and could therefore potentially be
mediators of the DKK1 effect (Fig. 4b). GSK3B, which is
reported to be a master negative regulator of diverse sig-
naling pathways including Wnt and insulin signaling [31],
displayed a 1.5-fold increased expression in replicate 1.
DLG4, which encodes a neuronal signaling and cell polar-
ity protein with a potential tumor suppressor role [32],
was 1.8-fold down-regulated in replicate 1. The other
reported DKK1 downstream proteins displayed only
minor changes in mRNA expression in NSCLC cisplatin-
refractory clones indicating that these are not downstream
targets in this setting (for deposited data, see Availability
of supporting data).
Basal DKK1 expression does not correlate to cisplatin
sensitivity
Given the observed up-regulation of DKK1 in cisplatin-
refractory NSCLC residual clones, we next analyzed basal
mRNA DKK1 expression levels in NSCLC cell lines with
the aim to reveal if there was a correlation between basal
DKK1 expression level and cisplatin sensitivity (Fig. 4c). A
heterogeneous expression level of DKK1 was evident
among the NSCLC cell lines with the highest DKK1
mRNA expression found in A549 and H23 cells, which
displayed an about 80- and 30-fold higher expression than
that observed in the U-1810 cells, which were used for the
gene expression profiling of residual clones (Fig. 4c, left
panel). We next set out to analyze if there was a correl-
ation between basal DKK1 expression on mRNA level and
cisplatin responsiveness. The NSCLC were subjected to
72 h continuous treatment with cisplatin and the area
under the curve (AUC) was used as a measurement of cis-
platin sensitivity. No correlation between baseline DKK1
expression and platinum sensitivity was however evident
(Fig. 4c, right panel). Of note, the cisplatin sensitivity was
relatively similar for the NSCLC cell lines which poten-
tially could explain the lack of correlation between DKK1
and cisplatin response Moreover, the mRNA levels of
the previously published markers of cisplatin resistance,
RRM1 and ERCC1, were also analyzed in relation to
cisplatin responsiveness (Fig. 4d-e). Their expression was
generally much less diverse than DKK1 in our NSCLC cell
line panel (Fig. 4d-e), and not correlated to their platinum
sensitivity.
Ablation of DKK1 expression sensitizes NSCLC cells to
cisplatin
In order to functionally connect DKK1 expression to cis-
platin response we next analyzed the effect of cisplatin
on DKK1 expression in NSCLC U-1810 cells at 48 and
72 h after a 1 h pulse treatment with 10 μM cisplatin
(Fig. 5a). As shown in Fig. 5a, transient cisplatin
Fig. 3 Validation of potential markers for intrinsic cisplatin refractoriness by q-RT-PCR. a Expression levels of FMN1 in cisplatin-surviving clones
from all three biological replicates were determined by microarray analysis (left panel) and q-RT-PCR (right panel). b Relative mRNA expression of
DKK1, XRCC2 and LGALS9 was determined by q-RT-PCR from replicates 1 and 3, respectively. For all mRNA analyses, 18S rRNA was used to control
for loading differences among the samples. The relative expression of each gene in cisplatin-surviving NSCLC residual clones is given as fold change
relative to untreated NSCLC clones which are set to one
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Fig. 4 In silico mapping of the DKK1 interactome using Ingenuity Pathway Analysis (IPA). a IPA-generated network built around DKK1 showing the
direct upstream transcriptional regulators. Those that showed concurrent up-regulation along with DKK1 in replicate 1 are shown in grey.
b IPA-generated network centered on DKK1 showing downstream signaling proteins that are indirectly regulated by DKK1. Those that were regulated
also in replicate 1 are shown in grey. For a and b, activation (►), inhibition (┤) or reports on both (┤►), indicates the regulation retrieved
from Ingenuity. c Left panel: Q-RT-PCR showing the mRNA expression level of DKK1 in a panel of NSCLC cell lines. 18S rRNA was used as a loading control.
Right panel: Correlation between baseline DKK1 mRNA expression and the cisplatin sensitivity of NSCLC cell lines after prolonged exposure (measured as
area under the curve (AUC) in MTT assay after 72 h continuous treatment, based on three experiments each performed in triplicate). mRNA expression
levels of RRM1 d and ERCC1 e together with correlation to cisplatin sensitivity as described in c
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Fig. 5 (See legend on next page.)
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exposure led to a slightly (1.3-fold) increased DKK1
mRNA expression at 48 h post treatment which was fur-
ther increased to 1.7-fold after 72 h. This may suggest
that cisplatin can elicit increased DKK1 expression as a
protective response. To explore if DKK1 is of import-
ance for cisplatin refractoriness, DKK1 expression was
ablated in NSCLC U-1810 and A549 cells using siRNA
and the effect on clonogenic survival was examined. An
80-90 % ablation of DKK1 mRNA expression was
achieved after transfection with either of two different
siRNA (si1 and si2) for 72 h as compared to the non-
targeting control siRNA in both NSCLC cell lines (Fig. 5b
and Additional file 3A). Notably, while cisplatin treat-
ment or knockdown of DKK1 per se each reduced the
colony formation capacity by up to 30 %, the combin-
ation of these treatments reduced colony formation by
50 % in U-1810 cells, demonstrating that DKK1 ablation
sensitizes these NSCLC cells to cisplatin (Fig. 5c-d).
Moreover, the same cisplatin-sensitizing effect of DKK1
knockdown was also evident in A549 cells but at a
slightly lower magnitude (Additional file 3B). In sum-
mary, these data indicate that knockdown of DKK1 con-
fers long term cisplatin sensitization in NSCLC cells and
results in reduced colony forming capacity.
The influence of DKK1 ablation on two of its IPA-
suggested indirect downstream targets i.e. p21WAF1/
Cip1 [22, 23] and GSK3B [28, 29] was also examined
in non-targeting or siDKK1-transfected U-1810, 24 h
after treatment with cisplatin for 1 h (Fig. 5e). Knock-
down of DKK1 per se increased the expression of
p21WAF1/Cip1 (Fig. 5e), implicating G1 arrest and pos-
sibly a senescent phenotype. In these p53-lacking U-
1810 cells [33], cisplatin generally reduced the
p21WAF1/Cip1 levels (Fig. 5e), however when siDKK1
was applied the reduction was smaller and a higher
p21WAF1/Cip1 expression level remained similar to un-
treated, non-targeting cells. This was supported in the
p53 wild type A549 cells where cisplatin increased
p21WAF1/Cip1, the increase is however more pronounced
after siDKK1 and cisplatin than after cisplatin alone
(Additional file 3C). The activity of GSK3B, which is de-
creased by phosphorylation at serine 9, was however not
significantly affected upon DKK1 ablation or cisplatin
treatment (Fig. 5e).
An increased activity of growth factor-regulated ki-
nases and up-regulated expression of anti-apoptotic
proteins are reported to contribute to a cisplatin-
refractory phenotype and to hamper cisplatin response
in solid tumor cells [4]. Phosphatidylinositol-3-kinase/v-
Akt murine thymoma viral oncogene homolog (PI3K/
AKT) signaling has been demonstrated to be increased in
cisplatin-refractory ovarian and colon cancer cells [34–36].
Moreover, the activation of AKT by Ser473 phosphoryl-
ation is reported to in part impair cisplatin-induced apop-
tosis by inactivating Bcl-2-associated death promoter
(BAD) or by increasing B-cell lymphoma 2 (Bcl-2) expres-
sion levels, thereby blocking Bcl-2 homologous antagonist/
killer/Bcl-2-associated X protein (BAK/BAX) activation [37,
38]. Accordingly, we examined the phosphorylation of
AKT (Ser473) and total AKT, PI3K and Bcl-2 expression
levels in these siDKK1-transfected, cisplatin-treated U-1810
cells (Figure 5e).
The basal level of phospho-AKT (Ser 473) was
slightly increased in DKK1-knocked cells, while cis-
platin reduced the levels in both non-targeting and
DKK1 siRNA-transfected cells. Only minor decreases
in total AKT and PI3K expression was seen after cis-
platin and/or DKK1 siRNA (Fig. 5e). Our results sug-
gest that although PI3K/AKT signaling might still be
players in this context, they do not seem to play a
prominent role in the increased cisplatin sensitivity of
cells lacking DKK1. On the other hand, in both U-1810
and A549 cells, Bcl-2 displayed a reduced expression in
DKK1-knocked cells compared to non-targeting, un-
treated cells (Fig. 5e, Additional file 3C). Similarly, cis-
platin caused a reduced expression of Bcl-2 and when
DKK1 siRNA and cisplatin were combined, down-
regulation was clearly evident. The expression of an-
other Bcl-2 family member, B-cell lymphoma-extra
large (Bcl-xL), was not altered in these samples (data not
shown). Albeit further studies on the role of apoptotic
signaling in DKK1 siRNA-mediated signaling to cisplatin is
needed, this data suggests that DKK1 ablation may
sensitize for cisplatin by down-regulating Bcl-2 expression.
(See figure on previous page.)
Fig. 5 Knockdown of DKK1 sensitizes NSCLC cells to cisplatin. (a) Q-RT-PCR shows the relative mRNA expression of DKK1 48 and 72 h after a short
pulse treatment of U-1810 cells with 10 μM cisplatin (1 h). The results of two separate experiments are shown. b U-1810 cells were transfected
with non-targeting (NT) or DKK1-specific siRNAs (si1 or si2); silencing of DKK1 mRNA expression was confirmed by q-RT-PCR. 18S rRNA was used
as a loading control. ***; p<0.005 vs NT control. c U-1810 cells were transfected with siRNA-DKK1 or NT siRNA and colony formation capacity was
assayed 9 days after treatment or not with a short pulse of cisplatin (1 h, 10 μM). Representative images of culture dishes for si1. d Clonogenic
capacity relative to untreated, NT siRNA-transfected cells for U-1810 si1 and si2. ***; p<0.005, **; p<0.01, when comparing DKK1 siRNA-transfected to
NT siRNA-transfected cells after cisplatin treatment. e Western blots showing p21WAF1/Cip1, phosphorylated GSK3B (Ser9) and AKT (Ser473), total AKT,
PI3K and Bcl-2 in U-1810 cells 24 h after treatment with cisplatin (1 h, 10 μM), which was performed on reseeded cells after the 72 h-transfection with
NT control or siRNA-DKK1 (si1). GAPDH was used as a loading control. (f-g) A2780 and its cisplatin-resistant subtype A2780 cis cells were transfected
with siRNA-DKK1 (si2) or NT. f siRNA silencing of DKK1 mRNA expression was confirmed by q-RT-PCR. **; p<0.01. g Cell viability was assayed 72 h after
continuous treatment with cisplatin, relative to untreated NT or si, using MTT assay. *; p<0.05
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DKK1 knockdown sensitizes ovarian cancer cells to
cisplatin
To validate our results from NSCLC in another tumor
type, we tested the ovarian cancer cell lines A2780 and
A2780 cis. A2780 cis is a subline of A2780 that devel-
oped acquired cisplatin resistance after exposure to
increasing concentrations of cisplatin over time [39].
Hence A2780 cis is about 7-fold more resistant to cisplatin
than its parental A2780. When applying DKK1 siRNA
(si2), DKK1 mRNA expression was down to about 50 % in
the parental A2780 cell line and to approximately 30 % in
A2780 cis versus their respective non-targeting control
(Fig. 5f). When assaying DKK1 mRNA levels, a higher
basal level (1.6-fold) was found in A2780 cis as compared
to A2780 cells (Fig. 5f). siDKK1 significantly sensitized the
A2780 , but not the A2780 cis cells, to cisplatin treatment
(Fig. 5g). In summary, these data indicate that knockdown
of DKK1 also can sensitize cells of other tumor types than
NSCLC to cisplatin. The acquired resistance of A2780 cis
was however more difficult to target and not possible to
revert at the level of DKK1 knockdown achieved in these
experiments. Nevertheless, A2780 cis had a higher base-
line DKK1 expression level which fits with our data of an
involvement of DKK1 in cisplatin resistance.
Discussion
Platinum-based compounds e.g. cisplatin and carbopla-
tin constitute the standard chemotherapy regimen for
NSCLC. Unfortunately a large proportion of the cases
display intrinsic resistance to these platinum drugs and
for yet another fraction, a platinum-refractory phenotype
typically develops during the treatment course [40]. In
this study, we aimed to identify molecular determinants
which drives a cisplatin-refractory phenotype and hence
could be used either as biomarkers of response or as
sensitizing targets for cisplatin in NSCLC. Our approach
of studying gene expression alterations in cisplatin-
surviving NSCLC clones is different from previous re-
ports using either very high, non-clinically achievable
cisplatin doses in short term treatment schedules [41] or
tumor cell models of acquired resistance [42]. The latter
is mostly reported to result in resistance mechanisms in-
volving up-regulation of membrane-associated drug ef-
flux pumps such as ATP-binding cassette proteins and
copper-extruding P-type ATPases [4, 8].
In our three biological replicates only FMN1 showed
altered expression in all three replicates, illustrating that
NSCLC cells surviving cisplatin pulse treatment have
heterogeneous clonogenic survival capacity and gene ex-
pression patterns. A possible reason may be that few
prominent long term effects are seen on the RNA level
9 days after cisplatin treatment. However, one interpret-
ation of this outcome is that cisplatin treatment can re-
sult in the expansion of different resistant clones in
different experiments. This clonal evolution hypothesis
has been demonstrated after epidermal growth factor re-
ceptor (EGFR)-ablative therapy, where a very low num-
ber of Kirsten rat sarcoma viral oncogene homolog
(KRAS)-mutated colorectal cancer cells emerged to be-
come the dominant clone among the surviving cells [43,
44]. Hence, we speculate that even small initial variations
in cisplatin responsiveness can induce certain clones to
become dominant. Optimally, if not limited by the min-
imal amounts needed for the analysis method, it would
be interesting to analyze multiples of clones separately to
explore their differences and heterogeneity further.
We and others have shown that a chemotherapy-
refractory cancer stem cell phenotype is evident in
certain NSCLC cell lines [14, 45]. However, this sphere-
forming capacity after enrichment in stem cell media was
not found in the NSCLC cell line used in this study
U-1810, suggesting that they might not contain an
appreciable proportion of stem-like cells and that the
heterogenic response of chemotherapy in this particu-
lar cell line likely is governed by other signaling cas-
cades. We observed the same cisplatin response in
clonogenic and MTT assays upon retreatment (Additional
file 4), therefore we could verify that using our single-
treatment setup, we were most likely only studying the
primary effects in the surviving clones that were selected
due to intrinsic refractoriness.
The one gene that was down-regulated in all three bio-
logical replicates was formin 1 (FMN1), a protein which
enhances formation of cell-cell adhesion [16]. As cis-
platin disrupts cell-cell adhesion before it induces apop-
tosis [46], one may speculate that the fraction of cells
with low FMN1 expression may be less responsive to the
adhesion-disruptive effects of cisplatin, and consequently
survive. However, by overexpressing FMN1 we were not
able to sensitize NSCLC cells to cisplatin indicating that
either FMN1 is not directly involved in regulating
cisplatin sensitivity or it acts in concert with other
signaling aberrations to confer survival advantage if
down-regulated, which not is recapitulated when forced
overexpression is used.
Analysis of each individual experiment revealed
DKK1, XRCC2 and LGALS9 as top scored differen-
tially up-regulated genes in cisplatin-surviving clones
from replicates 1 and 3, respectively. It is well docu-
mented that cisplatin treatment activates multiple
DNA damage signaling cascades, and here we found
an increased expression of XRCC2, a member of the
homologous recombination repair pathway, in cisplatin-
refractory residual NSCLC clones. This up-regulation
might be due to inherent properties of the cells, or alter-
natively, a selective pressure on the surviving clones to
up-regulate proteins involved in DNA repair to withstand
the damage. In line with our data, mouse embryonic
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fibroblasts deficient in XRCC2 are reported to be
hypersensitive to cisplatin treatment [47], further
pointing towards a connection between high XRCC2
expression levels and cisplatin resistance. Albeit LGALS9
has not yet been implicated in NSCLC or in a
chemotherapy-refractory phenotype of other tumor
cells, various galectins such as galectin-1 and -3 were
reported to have a role in driving a chemotherapy-
refractory phenotype [48, 49].
Importantly, we demonstrate that DKK1 has a role
in the intrinsic platinum responsiveness of NSCLC, as
siRNA-mediated ablation of DKK1 sensitized NSCLC
cells to cisplatin and reduced their clonogenic survival
potential. DKK1 is a secreted protein with dual anti-
and pro-survival functions in different tumor types.
For instance, DKK1 may act as a tumor suppressor
through inhibition of Wnt/β-catenin signaling and is
reported to activate apoptosis in multiple tumor types
e.g breast cancer, renal cell carcinoma, melanoma and
choriocarcinoma [50–53]. In head and neck cancer
cells, decreased DKK1 expression was associated with
acquired cisplatin resistance [42], whereas overexpres-
sion of DKK1 in a glioma cell line sensitized these cells to
DNA damaging agents including cisplatin [54]. Some of
these data are opposed to our study in which DKK1 was
upregulated in cisplatin-surviving NSCLC clones and its
knockdown conferred cisplatin sensitivity. These differ-
ences could possibly be attributed to tumor type specific
divergences in signaling cascades, or in mechanisms of
acquired cisplatin resistance. Our results of cisplatin
sensitization from NSCLC were however validated also in
ovarian cancer cells which were sensitized to cisplatin
upon siRNA knockdown of DKK1. Yet we could not
sensitize the acquired cisplatin-resistant subclone A2780
cis at the level of knockdown achieved in our experiments.
Our interpretation is that DKK1 regulates intrinsic cis-
platin resistance, still it may not be the main driver of ac-
quired cisplatin resistance.
Multiple studies have demonstrated an oncogenic
role of DKK1 in diverse tumor types such as multiple
myeloma, hepatoblastoma, Wilm’s tumor and hormone-
resistant breast cancer [55–57]. Moreover, high serum
level of DKK1 has been detected in patients with NSCLC
and esophageal carcinoma where it was associated with
tumor progression and poor outcome of these malignan-
cies suggesting that DKK1 in these tumor malignancies
may have an oncogenic role [18, 20, 58]. Using the cBio-
Portal for Cancer Genomics (cbioportal.org) [59, 60]
which integrates data from several databases including
The Cancer Genome Atlas, we found that DKK1 was
altered at the level of either mRNA upregulation, muta-
tion, homozygous deletion or amplification in a total of
6-9 % of lung adeno- or squamous cell carcinoma pa-
tients [61, 62]. In the adenocarcinoma population, the
mentioned alterations in DKK1 were also linked to a
significantly reduced overall survival [62], further sup-
porting the importance of DKK1 in NSCLC. Yet it re-
mains to be demonstrated if DKK1 regulate intrinsic
cisplatin sensitivity in vivo. Such studies could be per-
formed using NSCLC patient-derived xenografts in
mice. To demonstrate that DKK1 is a predictor of cis-
platin refractoriness in vivo in NSCLC patients is more
challenging as it would require a biopsy of primary
tumor and metastasis prior and post cisplatin treatment
which is not a standard routine in our clinic at present.
Hence a controlled clinical trial would be required in
order to adequately address this issue.
Through bioinformatics analysis of DKK1, we identi-
fied a number of putative transcription regulators of this
gene. Specifically, ectopic expression of the Wnt signal-
ing components TCF4 as well as active β-catenin induce
transcription of the DKK1 gene, and the DKK1 promoter
contains several TCF4 response elements, which fits well
with our data of co-regulated TCF4 and DKK1 [63].
DNAJB6 is known to activate DKK1 expression and also
had an increased expression in our data demonstrating a
regulation which fits earlier reported alterations [64]. In
contrast, EZH2 and HDAC2 which cause repression of
DKK1 according to literature [65–67], also showed in-
creased expression in our data. However, at least the
HDAC2 effects were reported to be p53-dependent [67]
and might therefore not apply in this cell system since
U-1810 cells lack p53 expression due to a truncating
mutation at p53 codon 172 [33]. Nevertheless, additional
validation experiments using siRNA/overexpression of
these proteins are needed to confirm a role for these
transcriptional regulators in the observed increased DKK1
expression in the cisplatin-refractory NSCLC clones.
IPA analysis identified p21WAF1/Cip1 to be a putative
downstream effector protein of DKK1, and p21WAF1/Cip1
is reported to negatively regulate the cell cycle, i.e. to
have a tumor suppressor role [68]. In rat mesenchymal
stem cells, addition of recombinant DKK1 protein de-
creased p21WAF1/Cip1 mRNA levels as well as the β-gal
staining, both indicators of senescence [23]. This is in
line with our data where DKK1 knockdown increased
p21WAF1/Cip1. Another IPA-retrieved report show how-
ever that transgenic mice with ectopic expression of
DKK1 in intestinal crypts has an up-regulated p21WAF1/
Cip1, possibly as a consequence of repression of c-myc
expression [22]. Overexpression or silencing of p21WAF1/
Cip1 induced or reduced, respectively, the cytotoxicity of
cisplatin in NSCLC A549 cells, signifying its importance
in cisplatin response in NSCLC [69]. After cisplatin
treatment, an increased expression of p21WAF1/Cip1 is
commonly seen in p53 wild type cell lines [70], like we
see in A549 cells (Additional file 3C). Although
p21WAF1/Cip1 was decreased in the p53-mutant U-1810
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cells after cisplatin, the level was higher after siDKK1
combined with cisplatin. Data from A549 cells support
this elevated p21WAF1/Cip1 level in siDKK1-ablated, cis-
platin-treated samples, despite their differential response to
cisplatin. Therefore we speculate that p21WAF1/Cip1 could
contribute to the reduced growth after DKK1 knockdown
and cisplatin by induction of G1 arrest and senescence.
GSK3B is a negative regulator of Wnt signaling pathway
and inhibition of GSK3B activity, i.e. increased p-Ser9, has
previously been shown to confer resistance to cisplatin in
lung and ovarian cancer cells [29, 71, 72]. The mRNA
expression was co-regulated with DKK1 in the cisplatin-
refractory cells but we did not see any change in the
phospho-GSK3B at the time point studied after siDKK1.
Still, the previously reported DKK1-regulation (Fig. 4b) of
both GSK3B (up) and DLG4 (down) was confirmed in
replicate 1.
No major changes were seen when we analyzed the
PI3K/AKT proteins which are known to be involved
in cisplatin-refractoriness [35]. We did however see
an almost 2-fold down-regulation in expression of the
anti-apoptotic protein Bcl-2 in both DKK1 siRNA and
DKK-1 ablated and cisplatin-treated samples in both U-
1810 and A549 cells (Fig. 5e and Additional file 3C). A re-
duced Bcl-2 allows for activation of pro-apoptotic BAK/
BAX, which is required for proper cisplatin response [37],
i.e. increased cisplatin-induced apoptosis. This could serve
as a mechanism for the sensitization since elevated levels
of Bcl-2 and other proteins within the same family e.g.
BCL-XL and MCL1 correlate with cisplatin resistance as
well as tumor recurrence in NSCLC and other cancers
[73–76]. Small molecule inhibitors for Bcl-2-like proteins
are also tested in clinical trials together with cisplatin [77].
Yet the importance of this down-regulation and the role
of DKK1 in regulating cisplatin-induced apoptotic signal-
ing would require further studies.
Apart from DKK1's role as a Wnt-signaling antagonist,
DKK1 overexpression correlates to an accumulation of
β-catenin in the cytoplasm or nucleus in clinical samples
from hepatocellular carcinoma [78]. We analyzed the
total level of β-catenin protein (data not shown) in the
samples from Fig. 5e but did however not detect any dif-
ferences at this time point.
Conclusions
Overall, we show here that NSCLC cells surviving a
short cisplatin pulse treatment have heterogeneous gene
expression patterns. We identify a number of genes as
potential markers of intrinsic cisplatin refractoriness,
such as DKK1, FMN1, XRCC2 and LGALS9. Moreover,
we demonstrate that DKK1 is a possible target that can
be used for cisplatin sensitizing purposes in NSCLC cells
and likely also other tumor types such as ovarian carcin-
oma. Our study therefore emphasize that further studies
should be performed with respect to DKK1 and its inter-
actome to reveal how it can be used to sensitize NSCLC
to platinum-based therapy, especially in an in vivo set-
ting such as NSCLC patient-derived xenografts.
Availability of supporting data
The data set supporting the results of this article is
available in NCBI's Gene Expression Omnibus [11]




Additional file 1: Hierarchical clustering was performed using
Partek Genomics Suite v6.6. Fold changes for genes in cisplatin-surviving
compared to untreated U-1810 cells for the replicates R1, R2 and R3 were
used, where red designates upregulated and blue downregulated genes. All
genes which were up- or down-regulated over 1.5-fold in any replicate were
included (for those regulated in more than one replicate, the additional
redundant ones were removed). (TIFF 1678 kb)
Additional file 2: A plasmid carrying FMN1 was transfected into
NSCLC U-1810 cells for 24 h, for which Lipofectamine-only served
as control. After another 24 h cells were tested for FMN1 expression
by western blot (A) or subjected to cisplatin treatment for 72 h after
which cell viability was examined by MTT (B). (A) Representative blot
for FMN1 expression in which β-tubulin served as loading control. (B)
Cell survival after FMN1 overexpression in U-1810 cells, given relative
to Lipofectamine-treated cells. Data shown is the mean ± SEM of three
experiments. (TIFF 120 kb)
Additional file 3: A549 cells were transfected with non-targeting
(NT) or DKK1-specific siRNA (si1). (A) Silencing of DKK1 mRNA
expression was confirmed by q-RT-PCR. 18S rRNA was used as a loading
control. ***; p < 0.005 vs NT control. (B) A549 cells were transfected with
siRNA-DKK1 or NT siRNA and colony formation capacity was assayed
9 days after treatment or not with a short pulse of cisplatin (1 h, 10 μM).
Clonogenic capacity relative to untreated, NT siRNA-transfected cells,
*; p < 0.05 (C) Western blots showing p21WAF1/Cip1 and Bcl-2 in
A549 cells 24 h after treatment with cisplatin (1 h, 10 μM), which
was performed on reseeded cells after the 72 h-transfection with
non-targeting control or siRNA-DKK1 (si1). GAPDH was used as a
loading control. (TIFF 423 kb)
Additional file 4: Retreatment of the pooled surviving U-1810-clones
from a first round of clonogenic survival, where the first treatment is
indicated for cisplatin-surviving (10 μM, Cisplatin as 1st) or untreated
(Untreated as 1st) clones. (A) The relative clonogenic survival in the first
(1st) round is depicted in the first white bar, the grey bars are data from
the retreated (2nd) experiment as described above, also using 10 μM
cisplatin. (B) MTT cell viability data. Doses used for the retreatment were
from 0.5-50 μM cisplatin and viability was analyzed after 72 h. Average ±
SD from three experiments, MTT was performed in triplicate. (TIFF 54 kb)
Abbreviations
AKT: v-Akt murine thymoma viral oncogene homolog; AUC: area under
the curve; BAD: Bcl-2-associated death promoter; BAK: Bcl-2 homologous
antagonist/killer; BAX: Bcl-2-associated X protein; Bcl-2: B-cell lymphoma
2; Bcl-xL: B-cell lymphoma-extra large; CDKN1A: cyclin-dependent kinase
inhibitor 1A; DKK1: Dickkopf WNT signaling pathway inhibitor 1; DLG4: disks large
homolog 4; DNAJB6: DnaJ homolog subfamily B member 6; EGFR: epidermal
growth factor receptor; EPHB2: ephrin type-B receptor 2; ERCC1: excision repair
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EZH2: enhancer of zeste homolog 2; FMN1: formin 1; GEO: Gene Expression
Omnibus; GSK3B: glycogen synthase kinase 3 beta; HDAC2: histone deacetylase
2; ICL: inter-strand crosslink; IPA: Ingenuity Pathway Analysis tool; KRAS: Kirsten rat
sarcoma viral oncogene homolog; LC: lung cancer; LGALS9: lectin,
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galactoside-binding, soluble 9; MAPK1: mitogen activated protein kinase 1;
MAPT: microtubule-associated protein tau; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl-tetrazolium; NSCLC: non-small cell lung cancer; p21WAF1/Cip1: p21 wild-
type activating fragment-1/cyclin-dependent kinase inhibitory protein-1;
PI3K: phosphatidylinositol-3-kinase; PLIER: probe logarithmic intensity error
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RRM1: ribonucleotide reductase M1; SCLC: small cell lung cancer;
SNORD: small nucleolar RNAs; TCF4: transcription factor 4; XRCC2: X-ray
repair cross-complementing protein 2.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RL, LL, KV, PH, and DZ designed the study. HS, LL, DZ and BM performed the
experiments. HS and LL summarized the data and drafted the manuscript.
PH, LL, MN and KV designed the revision experiments and MN and LL
conducted these experiments with PH/KV helping out in their evaluation. All
authors gave input to the manuscript and contributed to the discussion/
conclusions of the study.
Acknowledgements
This research was supported by grants from the Swedish Cancer Society
(grant agreement 120761/2012), the Cancer Society in Stockholm (to RL, KV
and PH), the Swedish Research Council (to RL, grant agreement 90266701/
2009), The Swedish National Board of Health and Welfare, the Stockholm
County Council, Karolinska Institutet research funds and the European Union
(FP6 Chemores, grant agreement 037669 and FP7 APO-SYS, grant agreement
200767). The financial support (to HS) from the Ministry of Higher Education
and Scientific Research in Iraqi-Kurdistan Regional Government and from the
Swedish Cancer Society (to LL) as a post-doctoral grant for lung cancer re-
search are greatly appreciated.
Received: 2 September 2014 Accepted: 1 September 2015
References
1. Cagle PT, Allen TC. Lung cancer genotype-based therapy and predictive
biomarkers: present and future. Arch Pathol Lab Med. 2012;136(12):1482–91.
2. Yeung K, Carlson JJ. Clinical and economic review of erlotinib in non-small-cell
lung cancer. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):411–23.
3. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a
cellular self-defense mechanism resulting from multiple epigenetic and
genetic changes. Pharmacol Rev. 2012;64(3):706–21.
4. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular
mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.
5. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA
repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant
chemotherapy. N Engl J Med. 2006;355(10):983–91.
6. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al.
Ribonucleotide reductase messenger RNA expression and survival in
gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Clin Cancer Res. 2004;10(4):1318–25.
7. Mohammed Ael S, Eguchi H, Wada S, Koyama N, Shimizu M, Otani K,
et al. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity
in non-small cell lung cancer cells. Exp Lung Res. 2012;38(9-10):463–74.
8. Oiso S, Takayama Y, Nakazaki R, Matsunaga N, Motooka C, Yamamura A,
Ikeda R, Nakamura K, Takeda Y, Kariyazono H: Factors involved in the
cisplatin resistance of KCP4 human epidermoid carcinoma cells. Oncol
Rep. 2014;31(2):719-26.
9. Bergh J, Nilsson K, Ekman R, Giovanella B. Establishment and
characterization of cell lines from human small cell and large cell
carcinomas of the lung. Acta Pathol Microbiol Immunol Scand A.
1985;93(3):133–47.
10. Rio DC, Ares Jr M, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol
(TRI reagent). Cold Spring Harb Protoc. 2010;2010:6. pdb prot5439.
11. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene
expression and hybridization array data repository. Nucleic Acids Res.
2002;30(1):207–10.
12. Salim H, Arvanitis A, de Petris L, Kanter L, Haag P, Zovko A, et al. miRNA-214
is related to invasiveness of human non-small cell lung cancer and directly
regulates alpha protein kinase 2 expression. Genes Chromosomes Cancer.
2013;52(10):895–911.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods.
2001;25(4):402–8.
14. Lundholm L, Haag P, Zong D, Juntti T, Mork B, Lewensohn R, et al.
Resistance to DNA-damaging treatment in non-small cell lung cancer
tumor-initiating cells involves reduced DNA-PK/ATM activation and
diminished cell cycle arrest. Cell Death Dis. 2013;4:e478.
15. Goodisman J, Souid AK. Constancy in integrated cisplatin plasma
concentrations among pediatric patients. J Clin Pharmacol.
2006;46(4):443–8.
16. Dettenhofer M, Zhou F, Leder P. Formin 1-isoform IV deficient cells
exhibit defects in cell spreading and focal adhesion formation. PLoS One.
2008;3(6):e2497.
17. Cedeno-Laurent F, Dimitroff CJ. Galectins and their ligands: negative
regulators of anti-tumor immunity. Glycoconj J. 2012;29(8-9):619–25.
18. Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, et al. Wnt
inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer
Res. 2010;70(13):5326–36.
19. Yonetani Y, Hochegger H, Sonoda E, Shinya S, Yoshikawa H, Takeda S, et al.
Differential and collaborative actions of Rad51 paralog proteins in cellular
response to DNA damage. Nucleic Acids Res.
2005;33(14):4544–52.
20. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al.
Dikkopf-1 as a novel serologic and prognostic biomarker for lung and
esophageal carcinomas. Cancer Res. 2007;67(6):2517–25.
21. Li S, Qin X, Guo X, Cui A, He Y, Wei S, et al. Dickkopf-1 is oncogenic and
involved in invasive growth in non small cell lung cancer. PLoS One.
2013;8(12):e84944.
22. Pinto D, Gregorieff A, Begthel H, Clevers H. Canonical Wnt signals are
essential for homeostasis of the intestinal epithelium. Genes Dev.
2003;17(14):1709–13.
23. Zhang DY, Wang HJ, Tan YZ. Wnt/b-Catenin Signaling Induces the
Aging of Mesenchymal Stem Cells through the DNA Damage Response
and the p53/p21 Pathway. PLoS One. 2011;6(6):e21397.
24. Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, et al.
Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is
associated with neuronal degeneration in Alzheimer's brain. J Neurosci.
2004;24(26):6021–7.
25. Salcedo-Tello P, Hernandez-Ortega K, Arias C. Susceptibility to GSK3beta-induced
tau phosphorylation differs between the young and aged hippocampus after
Wnt signaling inhibition. J Alzheimers Dis. 2014;39(4):775–85.
26. Zhang QG, Wang R, Khan M, Mahesh V, Brann DW. Role of Dickkopf-1, an
antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced
neuroprotection and attenuation of tau phosphorylation. J Neurosci.
2008;28(34):8430–41.
27. Gortazar AR, Martin-Millan M, Bravo B, Plotkin LI, Bellido T. Crosstalk
between caveolin-1/extracellular signal-regulated kinase (ERK) and
beta-catenin survival pathways in osteocyte mechanotransduction. J Biol
Chem. 2013;288(12):8168–75.
28. Fortress AM, Schram SL, Tuscher JJ, Frick KM. Canonical Wnt signaling is
necessary for object recognition memory consolidation. J Neurosci.
2013;33(31):12619–26.
29. Guo AJ, Choi RC, Cheung AW, Chen VP, Xu SL, Dong TT, et al. Baicalin, a
flavone, induces the differentiation of cultured osteoblasts: an action via the
Wnt/beta-catenin signaling pathway. J Biol Chem.
2011;286(32):27882–93.
30. Kuhnert F, Davis CR, Wang HT, Chu P, Lee M, Yuan J, et al. Essential
requirement for Wnt signaling in proliferation of adult small intestine and
colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci U
S A. 2004;101(1):266–71.
31. Gillespie JR, Bush JR, Bell GI, Aubrey LA, Dupuis H, Ferron M, et al. GSK-3beta
function in bone regulates skeletal development, whole-body metabolism,
and male life span. Endocrinology.
2013;154(10):3702–18.
32. Roberts S, Delury C, Marsh E. The PDZ protein discs-large (DLG): the 'Jekyll
and Hyde' of the epithelial polarity proteins. FEBS J.
2012;279(19):3549–58.
Salim et al. BMC Cancer  (2015) 15:628 Page 14 of 16
33. Sirzen F, Zhivotovsky B, Nilsson A, Bergh J, Lewensohn R. Spontaneous and
radiation-induced apoptosis in lung carcinoma cells with different intrinsic
radiosensitivities. Anticancer Res. 1998;18(2A):695–9.
34. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK,
et al. AKT and mTOR phosphorylation is frequently detected in ovarian
cancer and can be targeted to disrupt ovarian tumor cell growth.
Oncogene. 2004;23(34):5853–7.
35. Yang X, Fraser M, Moll UM, Basak A, Tsang BK. Akt-mediated cisplatin
resistance in ovarian cancer: modulation of p53 action on caspase-
dependent mitochondrial death pathway. Cancer Res. 2006;66(6):3126–36.
36. Zhang J, Zhang LL, Shen L, Xu XM, Yu HG. Regulation of AKT gene
expression by cisplatin. Oncol Lett. 2013;5(3):756–60.
37. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the
Bcl-2 protein family: implications for physiology and therapy. Nat Rev Mol
Cell Biol. 2014;15(1):49–63.
38. Fulda S. Modulation of mitochondrial apoptosis by PI3K inhibitors.
Mitochondrion. 2013;13(3):195–8.
39. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie
KG, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant
human ovarian cancer cell line and its use in evaluation of platinum
analogues. Cancer Res. 1987;47(2):414–8.
40. Chang A. Chemotherapy, chemoresistance and the changing treatment
landscape for NSCLC. Lung Cancer. 2011;71(1):3–10.
41. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a
and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res.
2010;70(5):1793–803.
42. Gosepath EM, Eckstein N, Hamacher A, Servan K, von Jonquieres G, Lage H,
et al. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is
associated with decreased DKK1 expression and can partially be reversed by
overexpression of DKK1. Int J Cancer. 2008;123(9):2013–9.
43. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy
in colorectal cancer. Nature. 2012;486(7404):532–6.
44. Diaz Jr LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular
evolution of acquired resistance to targeted EGFR blockade in colorectal
cancers. Nature. 2012;486(7404):537–40.
45. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification
and expansion of the tumorigenic lung cancer stem cell population. Cell
Death Differ. 2008;15(3):504–14.
46. Imamdi R, de Graauw M, van de Water B. Protein kinase C mediates
cisplatin-induced loss of adherens junctions followed by apoptosis of renal
proximal tubular epithelial cells. J Pharmacol Exp Ther.
2004;311(3):892–903.
47. Tsaryk R, Fabian K, Thacker J, Kaina B. Xrcc2 deficiency sensitizes cells to
apoptosis by MNNG and the alkylating anticancer drugs temozolomide,
fotemustine and mafosfamide. Cancer Lett. 2006;239(2):305–13.
48. Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL, et al. Galectin-1 promotes
lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK,
and cyclooxygenase-2. Clin Cancer Res. 2012;18(15):4037–47.
49. Kobayashi T, Shimura T, Yajima T, Kubo N, Araki K, Wada W, et al.
Transient silencing of galectin-3 expression promotes both in vitro and
in vivo drug-induced apoptosis of human pancreatic carcinoma cells.
Clin Exp Metastasis. 2011;28(4):367–76.
50. Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD. Dkk-1 secreted by mesenchymal
stem cells inhibits growth of breast cancer cells via depression of Wnt
signalling. Cancer Lett. 2008;269(1):67–77.
51. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Ueno K, et al. Wnt
antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis
and inhibits proliferation in human renal cell carcinoma. Int J Cancer.
2011;128(8):1793–803.
52. Liu S, Howell P, Ren S, Fodstad O, Zhang G, Samant R, et al. Expression and
functional analysis of the WAP four disulfide core domain 1 gene in human
melanoma. Clin Exp Metastasis. 2009;26(7):739–49.
53. Peng S, Miao C, Li J, Fan X, Cao Y, Duan E. Dickkopf-1 induced apoptosis in
human placental choriocarcinoma is independent of canonical Wnt
signaling. Biochem Biophys Res Commun. 2006;350(3):641–7.
54. Shou J, Ali-Osman F, Multani AS, Pathak S, Fedi P, Srivenugopal KS. Human
Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and
its overexpression sensitizes brain tumor cells to apoptosis following
alkylation damage of DNA. Oncogene.
2002;21(6):878–89.
55. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of
the Wnt-signaling antagonist DKK1 in the development of osteolytic
lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483–94.
56. Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer CG, et al.
Overexpression of human Dickkopf-1, an antagonist of wingless/WNT
signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest.
2003;83(3):429–34.
57. Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J,
et al. The Wnt pathway regulator DKK1 is preferentially expressed in
hormone-resistant breast tumours and in some common cancer types. Br J
Cancer. 2007;96(4):646–53.
58. Na Y, Lee SM, Kim DS, Park JY. Promoter methylation of Wnt antagonist
DKK1 gene and prognostic value in Korean patients with non-small cell
lung cancers. Cancer Biomark. 2012;12(2):73–9.
59. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio
cancer genomics portal: an open platform for exploring multidimensional
cancer genomics data. Cancer Discov. 2012;2(5):401–4.
60. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al.
Integrative analysis of complex cancer genomics and clinical profiles using
the cBioPortal. Sci Signal. 2013;6(269):l1.
61. Cancer Genome Atlas Research Network. Comprehensive genomic
characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–25.
62. Cancer Genome Atlas Research Network. Comprehensive molecular
profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50.
63. Gonzalez-Sancho JM, Aguilera O, Garcia JM, Pendas-Franco N, Pena C, Cal S,
et al. The Wnt antagonist DICKKOPF-1 gene is a downstream target of
beta-catenin/TCF and is downregulated in human colon cancer. Oncogene.
2005;24(6):1098–103.
64. Mitra A, Menezes ME, Shevde LA, Samant RS. DNAJB6 induces degradation
of beta-catenin and causes partial reversal of mesenchymal phenotype.
J Biol Chem. 2010;285(32):24686–94.
65. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, et al. EZH2-mediated
concordant repression of Wnt antagonists promotes beta-catenin-dependent
hepatocarcinogenesis. Cancer Res. 2011;71(11):4028–39.
66. Hussain M, Rao M, Humphries AE, Hong JA, Liu F, Yang M, et al. Tobacco
smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer
cells. Cancer Res. 2009;69(8):3570–8.
67. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional
activities through regulation of p53-DNA binding activity. Cancer Res.
2007;67(7):3145–52.
68. Romanov VS, Pospelov VA, Pospelova TV. Cyclin-dependent kinase inhibitor
p21(Waf1): contemporary view on its role in senescence and oncogenesis.
Biochemistry (Mosc). 2012;77(6):575–84.
69. Wang H, Zhu LJ, Yang YC, Wang ZX, Wang R: MiR-224 promotes the
chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating
G/S transition and apoptosis by targeting p21. Br J Cancer. 2014;111(2):339-54.
70. Qu K, Lin T, Wei J, Meng F, Wang Z, Huang Z, et al. Cisplatin induces cell
cycle arrest and senescence via upregulating P53 and P21 expression in
HepG2 cells. Nan Fang Yi Ke Da Xue Xue Bao. 2013;33(9):1253–9.
71. Cai G, Wang J, Xin X, Ke Z, Luo J. Phosphorylation of glycogen synthase
kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells.
Int J Oncol. 2007;31(3):657–62.
72. Gao Y, Liu Z, Zhang X, He J, Pan Y, Hao F, et al. Inhibition of cytoplasmic
GSK-3beta increases cisplatin resistance through activation of Wnt/beta-
catenin signaling in A549/DDP cells. Cancer Lett. 2013;336(1):231–9.
73. Erovic BM, Pelzmann M, Grasl M, Pammer J, Kornek G, Brannath W, et al.
Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression
might predict primary response against radiotherapy and chemotherapy in
patients with locally advanced squamous cell carcinomas of the head and
neck. Clin Cancer Res. 2005;11(24 Pt 1):8632–6.
74. Han JY, Hong EK, Choi BG, Park JN, Kim KW, Kang JH, et al. Death receptor 5
and Bcl-2 protein expression as predictors of tumor response to
gemcitabine and cisplatin in patients with advanced non-small-cell lung
cancer. Med Oncol. 2003;20(4):355–62.
75. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, et al. Bcl-2
blocks cisplatin-induced apoptosis and predicts poor outcome following
chemoradiation treatment in advanced oropharyngeal squamous cell
carcinoma. Clin Cancer Res. 2009;15(5):1645–54.
76. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, et al. Expression
of Bcl-xL in ovarian carcinoma is associated with chemoresistance and
recurrent disease. Gynecol Oncol. 2005;96(2):287–95.
Salim et al. BMC Cancer  (2015) 15:628 Page 15 of 16
77. Jain HV, Meyer-Hermann M. The molecular basis of synergism between
carboplatin and ABT-737 therapy targeting ovarian carcinomas. Cancer Res.
2011;71(3):705–15.
78. Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of DKK1 is
associated with cytoplasmic/nuclear beta-catenin accumulation and poor
prognosis in hepatocellular carcinomas. J Hepatol. 2009;50(5):948–57.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Salim et al. BMC Cancer  (2015) 15:628 Page 16 of 16
